Until recently, biotech companies tended to be founded with a focus on a single technology or biological pathway. An early exemplar of this was Genentech, founded in 1976 on the promise of recombinant DNA to generate proteins relevant for human health.1 Proof of concept came with the production of the hormone somatostatin in 1977, and the company made its synthetic insulin breakthrough in 1978, alleviating the need to harvest the protein from animal pancreases.
{iframe}https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/a-new-portfolio-model-for-biotech{/iframe}